Glen Eagle Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Glen Eagle Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.4K	Buy	180 +176	+4,400%	+$82.1K	0.01%	364
2025 Q4	$1.81K	Sell	4 -9	-69%	-$3.88K	﹤0.01%	892
2025 Q3	$5.09K	Sell	13 -6	-32%	-$2.51K	﹤0.01%	783
2025 Q2	$8.46K	Hold	19	–	–	﹤0.01%	671
2025 Q1	$9.21K	Hold	19	–	–	﹤0.01%	651
2024 Q4	$7.65K	Hold	19	–	–	﹤0.01%	691
2024 Q3	$8.84K	Buy	19 +4	+27%	+$1.92K	﹤0.01%	680
2024 Q2	$7.03K	Buy	+15	New	+$6.51K	﹤0.01%	707
2023 Q1	–	Sell	-2	Closed	-$578	–	1215
2022 Q4	$578	Buy	+2	New	+$610	﹤0.01%	1064
2022 Q1	–	Sell	-20	Closed	-$4.39K	–	978
2021 Q4	$4.39K	Hold	20	–	–	﹤0.01%	722
2021 Q3	$3.63K	Hold	20	–	–	﹤0.01%	850
2021 Q2	$4.03K	Hold	20	–	–	﹤0.01%	840
2021 Q1	$4.3K	Hold	20	–	–	﹤0.01%	790
2020 Q4	$4.73K	Buy	+20	New	+$4.59K	﹤0.01%	750

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Glen Eagle Advisors's VRTX Position: Q1 2026 in Review

Glen Eagle Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 4,400% in Q1 2026, buying an estimated $82.1K and bringing the position to 180 shares worth $80.4K. The position accounts for 0.01% of the portfolio, ranked #364.

Glen Eagle Advisors first reported a position in VRTX in Q4 2020 and has held it in 14 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Glen Eagle Advisors held 180 shares of Vertex Pharmaceuticals worth $80.4K as of Q1 2026.
Glen Eagle Advisors bought 176 Vertex Pharmaceuticals shares in Q1 2026, an estimated $82.1K.
Vertex Pharmaceuticals made up 0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #364 holding.
Glen Eagle Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.